At the 12th World Conference on Lung Cancer, drug maker Eli Lilly and Co. touted the benefits of the use of their drug ALIMTA to treat patients with malignant pleural mesothelioma.
Data from two large, open label studies was presented at the conference. According to the reports, patients involved in the trials experienced one-year survival rates above 50 percent when treated with ALIMTA or ALIMTA-based regimens for malignant pleural mesothelioma (MPM) in both a first-line and second-line setting.
One of the largest studies ever conducted among mesothelioma victims, the triple-arm, first-line study involved 2,023 patients who received either ALIMTA alone, ALIMTA combined with cisplatin, or ALIMTA and carboplatin. All three arms demonstrated clinically similar one-year survival rates with ALIMTA plus cisplatin producing slightly better results.
“The initial clinical trial results for ALIMTA in malignant pleural mesothelioma were definitely considered a medical breakthrough when they were unveiled just three years ago,” said Richard Gaynor, M.D., vice president, cancer research and global oncology platform leader for Lilly. “It is encouraging that these open-label studies show real world patient treatment outcomes that are consistent with those from the controlled clinical research environment. In my opinion, this is clinically meaningful information to the practicing oncologist.”